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SARS-Coronavirus-2 nucleocapsid protein measured in blood using a Simoa ultra-sensitive 
immunoassay differentiates COVID-19 infection with high clinical sensitivity. 
One Sentence Summary:  SARS-CoV-2 nucleocapsid protein (N-protein) measured in serum, plasma, and 
dried blood spots (DBS) via ultrasensitive immunoassay can be used to differentiate PCR+ from PCR- 
patients, even if asymptomatic.   
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Abstract.   
The COVID-19 pandemic continues to have an unprecedented impact on societies and economies 
worldwide.  Despite rapid advances in diagnostic test development and scale-up, there remains an 
ongoing need for SARS-CoV-2 tests which are highly sensitive, specific, minimally invasive, cost-effective 
and scalable for broad testing and surveillance. Here we report development of a highly sensitive single 
molecule array (Simoa) immunoassay on the automated HD-X platform for the detection of SARS-CoV-2 
Nucleocapsid protein (N-protein) in venous and capillary blood (fingerstick). In pre-pandemic and clinical 
sample sets, the assay has 100% specificity and 97.4% sensitivity for serum / plasma samples. The limit of 
detection (LoD) estimated by titration of inactivated SARS-CoV-2 virus is 0.2 pg/ml, corresponding to 0.05 
 . CC-BY-NC 4.0 International licenseIt is made available under a 
 is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)
The copyright holder for this preprint this version posted August 28, 2020. .https://doi.org/10.1101/2020.08.14.20175356doi: medRxiv preprint 
2 
 
Median Tissue Culture Infectious Dose (TCID50) per ml, > 2000 times more sensitive than current EUA 
approved antigen tests.  No cross-reactivity to other common respiratory viruses, including hCoV229E, 
hCoVOC43, hCoVNL63, Influenza A or Influenza B, was observed. We detected elevated N-protein 
concentrations in symptomatic, asymptomatic, and pre-symptomatic PCR+ individuals using capillary 
blood from a finger-stick collection device. The Simoa SARS-CoV-2 N-protein assay has the potential to 
detect COVID-19 infection via antigen in blood with performance characteristics similar to or better than 
molecular tests, while also enabling at home and point of care sample collection. 
Introduction.   
In November 2019, the SARS-CoV-2 (severe acute respiratory syndrome coronavirus-2) emerged in 
Wuhan, China and since has caused a worldwide pandemic 1.  To date, the USFDA has granted Emergency 
Use Authorization (EUA) to three types of SARS-CoV-2 assays: molecular testing or PCR, antibody testing 
or serology, and antigen testing2. Molecular testing for viral RNA is the primary diagnostic modality for 
active infection, while serology measures anti-SARS-CoV2 antibodies post-infection 3,4.  Although RT-PCR-
based molecular testing for viral RNA in respiratory specimens is the primary diagnostic tool for active 
infection, concerns have been raised about the risk of false negative results associated with the use of 
nasal and nasopharyngeal swabs 5. This is especially true in the days before symptom onset; Kucirka et al. 
have found the probability of a false negative result in an infected person to decrease from 100% on day 
1 post-infection to 67% on day 4.  On day 5, the median time for symptoms to appear, molecular tests still 
had a 38% probability of producing a false negative result and declined no further than 20% in the days 
that followed, when the infection should be most detectable6. Furthermore, the complexity, cost, supply 
chain challenges, and relatively lower throughput of RT-PCR results are disadvantages toward fulfilling 
large-scale testing required to enable societies to re-open7.   
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Antigen detection by immunoassay has the potential advantages of a simpler workflow, faster turn-
around time, lower cost, and with a supply chain diversified from PCR. However, currently available 
antigen tests are generally less sensitive than PCR, for example one lateral flow assay has been reported 
to have percent positive agreement (PPA) with qRT-PCR of only 24 to 30%8,9.  Two EUA cleared antigen 
tests have claimed sample types of nasopharyngeal or nasal swabs with 96.7% and 84% PPA with PCR and 
should greatly enhance diagnostic capacity, but they are still subject to the same sampling challenges 
associated with nasal or nasopharyngeal swabs and less analytical sensitivity relative to PCR 10,11. 
SARS-CoV-2 infections can present unusual peripheral symptoms, such as stroke, heart attack, kidney 
damage, neurological symptoms, and COVID-toe. These clinical manifestations suggest that this 
respiratory virus can migrate from the lungs into the bloodstream. Mehra et al. first described evidence 
of SARS-CoV-2 peripheral involvement during post-mortem histological examination of effected tissues, 
including electron microscopy images of viral inclusion structures in endothelial cells 12. It was 
hypothesized that SARS-CoV-2 infection may facilitate the induction of endothelitis in multiple organs as 
a direct consequence of viral involvement. Wölfel et al. reported that SARS-Cov-2 virus was not detectable 
in blood using molecular diagnostic techniques13, but additional later studies have found evidence that 
plasma viremia may play a significant role in disease course and that viral loads in plasma may predict risk 
of death14.  
Recently, Ogata et al. measured SARS-CoV-2 antigens (S1 antigen, spike antigen, N-protein) in venous 
blood for the first time15. They hypothesized that detection of viral antigen could be used to stratify 
patients between mild and severe cases, but that asymptomatic or mild cases would not have measurable 
levels. If true, this would be a distinct difference between SARS-CoV-2 and SARS-CoV, as patients of the 
latter had measurable levels of N-protein in blood up to 3 weeks after symptom onset, and measurement 
of N-protein had 94% PPA up to 5 days compared to PCR 16. 
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We theorized that by leveraging the exceptional sensitivity of Single Molecule Array (Simoa) immunoassay 
technology, we could detect and quantitate SARS-CoV-2 antigen directly in serum and plasma from venous 
collection and capillary blood acquired by commercially available finger-stick collection devices. Here we 
report the development of a blood-based assay for SARS-CoV-2 N-protein that potentially shows detection 
of clinically significant viral loads in active and pre-symptomatic COVID-19 infections, avoiding the use of 
swabs and the need to sample nasopharyngeal or nasal fluids. 
Materials and Methods.  
Samples. Healthy pre-pandemic serum and plasma samples (collected before December 2019) were 
obtained from BiolVT (Westbury, NY). Commercially sourced serum and plasma samples from COVID-19 
positive donors, as demonstrated by positive RT-PCR test, were obtained from BiolVT and from Boca 
Biolistics (Pompano Beach, FL; hereafter ‘BocaBio’). Samples were collected between April 06 and June 
17, 2020. RT-PCR was performed between March 06 and June 12, 2020.  Plasma samples from 
hospitalized COVID-19 patients, as demonstrated by positive RT-PCR test, were provided by Drs. Jacob 
Nattermann, University of Bonn, Germany. Samples were collected between March 30 and April 22, 
2020. RT-PCR was performed between March 30 and April 15, 2020. The study was approved by the 
Institutional Review board of the University Hospital Bonn (134/20). Patients were included after 
providing written informed consent. In COVID-19 patients who were not able to consent at the time of 
study enrollment, consent was obtained after recovery. Dried blood microsamples were collected using 
Mitra® Devices (Neoteryx, Torrance, CA) from staff and residents of CT Baptist Care Homes Inc. (CTCH 
cohort). COVID-19 status of each donor was determined by RT-PCR test and DBS samples were collected 
at two time points, one week apart, for measurement of N-protein and IgG levels by Simoa. Gamma-
inactivated SARS-CoV-2 virus was obtained from BEI (beiresources.org), heat-inactivated SARS-CoV-2 
and microbial specimens for cross-reactivity testing were obtained from ZeptoMetrix. 
(zeptometrix.com).  
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Assay Development.  In Research Use Only (RUO) products Single Molecule Array (Simoa) technology 
offers sensitivity on average 1000-fold greater than traditional immunoassays 17,18. In brief, the technology 
involves performing a paramagnetic microbead–based sandwich ELISA, followed by isolation of individual 
capture beads in arrays of femtoliter-sized reaction wells. Singulation of capture beads within microwells 
permits buildup of fluorescent product from an enzyme label, so that signal from a single immunocomplex 
can be detected with a CCD camera in 30 seconds. At very low analyte concentrations, Poisson statistics 
dictate that bead-containing microwells in the array will contain either a single labeled analyte molecule 
or no analyte molecules, resulting in a digital signal of either “active” or “inactive” wells. Data collection 
involves counting active wells corresponding to single enzyme labels. At higher analyte concentrations, 
digital measurements transition to analog measurements of total fluorescence intensity. Simoa data are 
reported as Average Enzymes per Bead (AEB). It is widely used in the field of neurodegenerative disease 
and recently, for the measurement of SARS-CoV-2-associated biomarkers 19,20. It has also been 
demonstrated to rival the sensitivity of PCR for monitoring HIV infection through measurement of the p24 
capsid protein in blood 21,22. 
SARS-CoV-2 N-protein Assay. Antibodies and antigens were obtained from commercial sources.  Eight 
different antibodies and five antigens were screened, resulting in more than 60 different test 
configurations.  The antibody and antigen combination that produced the best signal / background ratio 
for both calibrator and positive samples was selected.  Diluent formulations, detector antibody and 
Streptavidin–β-Galactosidase concentrations were then optimized, as well as assay protocols (2-step vs 
3-step; incubation times).  A phosphate-based sample diluent was selected with EDTA to inhibit proteases, 
heterophilic blocker and a detergent to help de-envelope and inactivate virus particles. 
SARS-CoV-2 IgG Assay. An assay was developed to monitor the serological response of IgG to the full-spike 
of SARS-CoV-2.  This assay has been submitted for EUA clearance (USFDA application EUA20164); 
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verification and validation details are planned to be released in product-specific validation reports and 
instructions for use upon product launch. 
Assay Verification.  N-protein Assay.  The assay was verified by testing 6 runs over 3 days over 2 lots, for 
a combined total of 12 runs.  Verified characteristics include precision, ad-mixture linearity, spike 
recovery, limit of blank (LoB), limit of detection (LoD), and limit of quantification (LoQ) for serum, K2 EDTA 
plasma, and dried blood spots (Supplementary Figure S1 and Table S1). Precision was determined using 2 
diluent-based controls and 3 matrix based spiked samples.  Limit of detection (LoD) was determined with 
gamma-inactivated SARS-CoV-2 virus diluted 6e6 fold into a serum from a negative donor, using stock 
with a TCID50 of 2.8e5 per mL (final TCID50 = 0.05 per mL), and testing 36 replicates over 3 days and 2 
different assay lots. Admixture linearity was demonstrated using negative matrix spiked with heat-
inactivated virus, and then mixed in varying ratios with a separate non-spiked matrix to create ten levels. 
We established a preliminary clinical cutoff by measuring N-protein levels in four SARS-CoV-2 negative 
cohorts: 1) pre-pandemic serum / plasma (N=100); 2) a panel of plasma samples sero-negative for SARS-
CoV-2 negative and sero-positive for common respiratory infections (N=36, Supplementary Table S2); 3) 
a panel of serum samples sero-negative for SARS-CoV-2 and sero-positive for other common 
coronaviruses (N=31, Supplementary Table S3); 4) PCR- DBS samples from CTCH (N=9). Data is shown in 
Supplementary Figure S2. 
Sample Types. Serum, K2EDTA plasma, and dried blood spots were used in the analyses. Serum and plasma 
were collected by normal processing methods, and stored frozen at -80C before analysis.  Serum and 
plasma samples were diluted 4-fold into assay diluent on the HD-X instrument before measurement.  
Dried blood spots (DBS) were collected using Mitra collection kits from Neoteryx according to standard 
protocols (https://www.neoteryx.com/home-blood-blood-collection-kits-dried-capillary-blood). Tips 
absorb 20 µl of whole blood and are then allowed to dry for at least 16 hours in a pouch with dessicant. 
Tips are extracted into 250 µl of assay diluent with shaking at 400 rpm overnight at 2 - 8℃, resulting in a 
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12.5-fold sample dilution. All sample results have been corrected for dilution factors, to represent the 
concentration within the sample matrix.   
Sample Matrix Correlation. To correlate serum and plasma matrices, matched samples from PCR+ donors 
were measured with the N-Protein assay. N-protein levels correlated between matrices with a slope of 
1.12 and an R2 of 0.995 (Supplementary Figure S3). To verify the recovery of N-protein from the Mitra tips, 
whole blood was collected into K2EDTA tubes, spiked with recombinant N-protein and then processed 
into either plasma or DBS. N-protein levels were measured in both sample types. N-protein levels 
correlate between matrices with R2 = 0.993 and a slope of 1.97. The concentration in DBS was 
approximately ½ of that in plasma, as expected due to the excluded volume of hematocrit which is 
separated from plasma (Supplementary Figure S4).   
DTT treatment of plasma samples. To determine whether seroconversion and antigen-masking by 
immunoglobulins plays a role in the decrease of N-protein signal, samples were treated with 10 mM DTT 
at 37°C for 15 minutes. To demonstrate the effectiveness of this treatment the following experiment was 
conducted: 1) negative serum was spiked with N-protein and measured on the N-protein assay; 2) a 500x 
concentration of anti-N-protein antibody was added and the sample was measured, resulting in a 60% 
decrease in antigen; 3) the sample spiked with both antigen and antibody was treated with DTT according 
to the protocol above and measured, resulting in a 75% rescue of antigen signal (Supplementary Figure 
S5).   
Cross reactivity studies. Cultured and inactivated pathogens were spiked into negative serum samples to 
attain 105 TCID50 per ml, using a minimum of 4x dilution of viral stock into serum. Some virus cultures 
had insufficiently high stock titer to achieve 105 TCID50 per ml, and these viruses were tested at the 
highest titer possible after a 4x dilution into serum. No cross-reactivity was observed, as detailed in 
Supplementary Table S4.    
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Results and Discussion.  
To determine the clinical utility of the N-protein assay for serum and plasma, we measured PCR+ samples 
from BocaBio and the University of Bonn, and pre-pandemic samples from BioIVT.  Figure 1 panel A 
represents only “first-draw” samples, in which every data point represents a unique donor.  This use-case 
is appropriate for a test that is intended to screen novel patients as positive or negative23. Our preliminary 
cutoff of 0.9 pg/mL (dashed line) confers a clinical sensitivity of 97.6% (37/38 positives >0.9 pg/ml) and 
clinical specificity of 100% (100/100 negatives < 0.9 pg/ml).   
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Figure 1. Simoa SARS-CoV-2 N Protein measurements differentiate pre-pandemic from PCR+ donors in serum and 
plasma. Panel A. Pre-pandemic sera from BioIVT (closed symbols), PCR+ sera from BocaBio (closed symbols) and the 
plasma samples from U. Bonn (open symbols). PCR+ samples are binned chronologically according to day-from-
symptom or, if asymptomatic, day- from-PCR (BocaBio) and day-from-hospitalization / PCR (U. Bonn). Each point 
represents a unique donor. Panel B. Measurements from all samples, including multiple longitudinal draws from the 
U. Bonn patients.  
We binned the samples by day, and in Figure 1 panel B we include multiple timepoints from longitudinal 
donors (Univ. Bonn) to develop an initial temporal profile of the viral antigen in blood. Using an 
immunoassay for SARS-CoV N-protein, Che et al. observed clinical sensitivity of 94%, 78% and 27% for 
blood samples within days 1-5, 6-10 and 11-20 of symptom onset 16. Our data shows similar performance, 
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albeit with enhanced sensitivity, notably after the 1st week of infection. This suggests the possibility that 
an ultrasensitive antigen assay could expand the diagnostic window beyond that addressable by the 
current EUA approved antigen assays that claim clinical sensitivity only within the first 5 to 7 days after 
onset of symptoms 10,11. To determine this, future studies will need to test a sample cohort with well-
defined clinical characteristics, in which the onset of infection and symptom are accurately known.  
We also measured anti-SAR-CoV-2 specific IgG in the longitudinal samples from the U. Bonn cohort (Figure 
2).  N-protein concentration in plasma was observed to decrease over time with a concurrent increase in 
anti-SARS-CoV2 IgG levels. By normalizing patient responses and using a four-parameter logistic 
regression to the average response, we find N-protein clearance to occur at 15.6 days and IgG plateau at 
7.7 days after hospitalization. Several of these patients had already undergone seroconversion prior to 
first collection; given that seroconversion for SARS-CoV-2 can occur between day 7 to 13 post-
symptom15,24, we estimate that N-protein clearance occurs between days 22 to 28 and IgG plateau 
between days 14-20 post-symptom, similar to timelines observed for SARS 16.  Ogata et al. also observed 
similar timelines for SARS-CoV-2, although in their study N-protein was generally not detectable once IgG 
levels had stabilized15, whereas we observed a window of approximately 7 days between IgG plateau and 
N-protein clearance during which both biomarkers are quantifiable. These data suggest the value of 
conducting additional studies to further characterize the relationship between IgG and N-protein levels in 
a larger sample set. 
To determine whether seroconversion and antigen-masking by immunoglobulins plays a role in the 
decrease of N-protein signal, we treated longitudinal samples from patient 5 with DTT to unmask potential 
antigen-antibody complexes. We observed a modest increase in N-protein levels of 27% after treatment 
on average (Figure 2 Patient 5). Considering the overall decrease of >1400% over the entire time-course, 
we hypothesize that antigen-masking plays a negligible role, and that instead N-protein levels decrease 
due to clearance from the blood.  
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Figure 2.  Plasma levels of anti-SARS-CoV-2 IgG increases concurrently with decreasing N-protein levels. Longitudinal 
samples from five patients in the U. Bonn cohort are shown. Samples from patient 5 were tested with and without 
DTT treatment (bottom left panel). Four-parameter logistic regression to the average, normalized concentration of 
N-protein and IgG (bottom right panel). 
To allow at-home or point-of-care collection of blood samples, we tested dried blood spots (DBS) collected 
with Mitra® tips (Neoteryx.com). These devices absorb 20 µl of capillary blood from a finger-stick, and 
users may subsequently store and ship them without cold-chain requirements. We measured N-protein 
levels in DBS patient samples collected in the presence of active COVID-19 infections using the Mitra 
devices (CTCH cohort). This long-term care facility has established a practice of testing residents and staff 
for COVID-19 weekly using an authorized molecular test. This enabled a comparison of the performance 
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of the Simoa SARS-CoV-2 N-Protein Assay against the gold-standard of PCR in the context of active and 
on-going COVID-19 infections; relative days of collection are shown in Table 1. 
Table 1. Sampling and testing timeline in CTCH study 
Collection 1 Day 1* Day 5  Collection 2   Day 8** Day 12 
PCR test 20 donors  
4 donors died 
1 declined 
7 new donors enrolled 
22 donors total 
 
DBS collection  20 donors   22 donors 
* PCR for two donors done on Day -2 and three donors on Day -1. 
**PCR for one donor on Day -5, one on Day 2 and one on Day 12. 
In Figure 3 panel A we show N-protein levels for both collections from CTCH, with connecting lines 
denoting changes in individual donor levels from week 1 to week 2. This data demonstrates 100% 
sensitivity and specificity of the Simoa N-protein assay compared to PCR, and notably the Simoa N-protein 
assay identified COVID-19 positive status for four donors that exhibited no symptoms over the course of 
infection (asymptomatic) and five donors that developed symptoms after sample collection (pre-
symptomatic). 
The time course of donor 12 in particular illustrated the ability of N-Protein in capillary blood to diagnose 
COVID-19 before symptom onset: enrolled as a negative control and tested PCR- on day 1; DBS sampled 
on day 5 showed elevated levels of N-Protein (first collection) before symptom onset; confirmed positive 
with PCR testing on day 7; symptoms developed on day 8; by day 15 recovered. Donor 12 may represent 
a false-negative PCR result that was detected using the N-protein assay, though PCR test and DBS 
collection were five days apart; future studies will aim to address this question through direct comparison 
of clinical sensitivity of PCR and the Simoa SARS-CoV-2 N-Protein assay on samples collected concurrently. 
Regardless, donor 12 exemplifies the ability of the Simoa SARS-CoV-2 N-Protein assay to detect pre-
symptomatic COVID-19 infection.  
False negative PCR results represent a significant challenge in the COVID-19 pandemic5. Kucirka et al. 
report the highest probability of PCR false-negative results before symptom onset, with the false-negative 
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rate decreasing from 100% to 67% in the first four days post-infection. On day 5, the median time for 
symptom-onset, the probability of a false negative result in a PCR-based molecular test was still 38% 6,26. 
Compounding the problem of poor clinical discrimination in pre-symptomatic patients, He et al. observed 
the highest viral load in throat swabs at time of symptom onset, and inferred that infectiousness will peak 
at or before symptom onset25. In this context, the ability of the Simoa SARS-CoV-2 N-Protein assay to 
detect pre-symptomatic individuals could be particularly important. 
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Figure 3.  SARS-CoV-2 N-protein levels measured in capillary blood (dried blood spots (DBS)) from CTCH residents 
and staff confirm PCR results. Panel A: PCR- samples are denoted in black (●), PCR+ in red (●), and PCR+ 
asymptomatic or pre-symptomatic in open red (○) with lines connecting samples from the same donor over two 
collections. Panel B: Donors grouped into PCR-, asymptomatic PCR+, pre-symptomatic PCR+ and symptomatic PCR+, 
as noted at time of confirmatory PCR. Only the first collection point is represented for each donor.     
In the CTCH cohort, 8 of the 14 PCR+ donors presented without symptoms even with elevated levels of N-
protein and in Figure 3 panel B, we separated donors into four groups: PCR-; asymptomatic PCR+ that did 
not show symptoms at any point during infection; pre-symptomatic PCR+ that did not show symptoms at 
the first collection but developed symptoms by the second collection; and symptomatic PCR+ that 
presented with symptoms at the first collection. Fully asymptomatic donors have a lower median level of 
N-protein; however we do not see different levels of N-protein between pre-symptomatic or symptomatic 
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donors. Ogata et al. suggested that viral antigen would only present in blood in severe or late-stage cases, 
however our data suggest that some mechanism exists for viral antigen to transfer to blood even in early 
and asymptomatic cases 15. Che et al. reported similar trends for SARS-CoV patients, who had a higher 
positive detection rate of N-protein in serum samples within the first 10 days of infection than that 
detected by RT-PCR in respiratory samples, an observation hypothesized to be associated in part with 
respiratory specimen collection variables leading to false negatives 16. 
In Figure 4 panel A we have ranked CTCH PCR+ donors by N-protein level, and color-coded results 
according to disease outcome: deceased; not recovered at collection 2; or recovered at collection 2.  In 
this limited sample set, we observe a trend of worse clinical outcome associated with higher N-protein 
level. Ogata et al. have observed a similar trend for viral antigen in blood15, and Fajnzylber et al. reported 
that viral-RNA load is associated with increased disease severity and mortality14.  
  
Figure 4.  Comparison of N-protein levels from DBS with clinical severity indicators in CTCH cohort. (A) SARS-CoV-2 
N protein concentrations at the initial sample collections. (B) N protein clearance after one week, and comparison 
to IgG levels. 
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In Figure 4 panel B, we have grouped donors into recovered (n=4) and not recovered (n=2) and display N-
protein and IgG levels for both collections.  Average N-protein level decreases 10-fold (1143 to 98 pg/ml) 
for recovered donors across both collection dates, contrasted with a higher starting average and more 
moderate decrease of 2-fold (2287 to 988 pg/ml) for not recovered donors. We measured low IgG levels 
for all donors at collection 1, suggesting that seroconversion had not yet occurred. At collection 2 we 
detected a slight IgG increase for some donors, but a large increase only for donor 1. This donor also had 
a concomitant, large decrease in N-protein, and was the only donor with high N-protein levels to recover 
by the 2nd collection. Serological assessment may complement the N-protein assay and help stratify 
outcomes of severe cases. All data for the CTCH cohort is shown in Supplementary Table S5.  
 Conclusion 
In summary, we have developed a blood-based assay for SARS-CoV-2 N-Protein and our studies 
demonstrate detection of clinically significant viral loads in active, pre-symptomatic and asymptomatic 
COVID-19 infections, using sample collection methods that avoid swabs and the need to sample 
nasopharyngeal or nasal fluids. Based on testing performed to date, we estimate a clinical sensitivity of 
97.4% in serum / plasma using two PCR+ cohorts and clinical specificity of 100% using a cohort of 100 pre-
pandemic samples.  We see no cross-reactivity to other common respiratory viruses, including hCoV229E, 
hCoVOC43, hCoVNL63, Influenza A or Influenza B. Using titers of gamma-inactivated virus we estimate 
the limit of detection (LoD) of our assay to be 0.05 TCID50, > 2000 times more sensitive than current 
antigen tests with EUA approval for use in nasal swabs10,11.   
We have demonstrated detection in capillary blood using the Neoteryx Mitra® dried blood spot (DBS) 
collection device, which enables at-home and point-of-care sample collection.  Using DBS samples, we 
successfully monitored disease status of staff and residents in the presence of active COVID-19 infections 
with clinical sensitivity comparable to molecular testing in our preliminary experiments. Higher 
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concentrations of N-protein associated with increased disease severity and mortality, and vice-versa 
clearance of the antigen associated with greater recoverability. 
We plan further studies to validate the ability of the SARS-CoV-2 N-Protein assay to diagnose COVID-19 
and determine if it has comparable or better sensitivity than molecular testing, including studies with 
larger, prospective cohorts with better characterized clinical symptoms and timelines.  In particular, we 
will attempt to conduct trials with well-defined onset of infection to determine the window of 
effectiveness of the SARS-CoV-2 N-Protein assay, which may be able to diagnose both earlier than 
molecular testing (pre-symptomatic infection) and later than current EUA cleared antigen tests (beyond 
one week post-symptom). 
The SARS-CoV-2 antigen assay has the potential to be available for widespread deployment through 
minimally invasive remote and home sample collection and utilization of the fully automated HD-X 
immunoassay platform. It is expected that this SARS-CoV-2 product candidate antigen assay may provide 
a new, orthogonal method for early detection of SARS-CoV-2 infection that can significantly and rapidly 
augment the accuracy and availability of the SARS-CoV-2 testing arsenal. 
Safe Harbor Statement: CAUTION: Investigational device. Limited by federal law to investigational use. Not 
available for sale. 
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Supplemental Information. 
 
          
Figure S1. Calibration curve of the Simoa SARS-CoV-2 N Protein Advantage Assay. Lower limit of 
quantitation (LLoQ) is shown as the dashed line, and calibrator concentrations are denoted on graph. 
 
Table S1. Performance characteristics of Simoa SARS-CoV-2 N Protein Advantage Assay. 
   Antigen Assay 
Minimum Required Dilution (MRD) 4x (serum and plasma) 
12.5x (DBS) 
Required Sample Volume 25 µl (serum and plasma) 
20 µl (DBS) 
Assay Range (adjusted for dilution) 0.9 – 800 pg/ml (serum and plasma) 
2.8 – 2500 pg/ml (DBS) 
Clinical Specificity  100%  
Clinical Sensitivity 97.6%  
Limit of Blank 0.1 pg/ml 
Limit of Detection 0.32 pg/ml (0.047 TCID50/ml) 
Limit of Quantification 0.91 pg/ml (0.094 TCID50/ml) 
Precision ~6% within-run 
~6% between-run 
~4% between-day 
Dilution Linearity ~102% recovery 
Spike Recovery ~98% 
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Figure S2. Seven sample cohorts were used to establish a preliminary clinical cutoff of 0.9 pg/ml for the 
SARS-CoV-2 N-Protein assay; sample numbers are shown as N in the axis label.  JN +ve was K2 EDTA plasma 
from PCR+ donors from the U. Bonn cohort. BocaBio (+ve) were PCR+ serum from that commercial 
supplier.  CT Care Home +ve (PCR+) and -ve (PCR-) were dried blood spot (DBS) samples from residents 
and staff of the care facility.  Pre-pandemic samples were a mixture of serum and K2 EDTA plasma from 
donors acquired before December 2019 purchased from BioIVT.  Respiratory Panel was K2 EDTA plasma 
purchased from BioIVT and from donors serologically confirmed to have been infected with combinations 
of H. influenza, RSV, influenza A, influenza B, parainfluenza (1-4), adenovirus, enterovirus, M. 
pneumoniae, Legionella, B. pertussis, and C. pneumoniae. Coronavirus Panel was serum purchased from 
BioIVT from donors serologically confirmed to have been infected with human coronaviruses-HKU, OC43, 
229E and NL63. Preliminary cutoff of 0.9 pg/ml was chosen to confer 100% specificity over all SARS-CoV-
2 negative sample cohorts.      
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Figure S3.  Matched serum and plasma samples from the same donors were found to have excellent 
correlation in N antigen levels between matrices.  Twenty matched samples from BocaBio confirmed to 
be PCR+ were tested in both serum and K2 EDTA plasma. 
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Figure S4. Whole blood drawn into a K2 EDTA plasma tube (3 donors) was spiked with known levels of 
recombinant N-protein.  It was then processed into neat plasma and in parallel into Dried Blood Spots 
using Neoteryx Mitra tips.  After extraction, both sample types were measured, showing a correlation of 
0.9926.  The concentration in DBS was approximately ½ of that in plasma, as expected due to the excluded 
volume of hematocrit which is separated from plasma. 
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Figure S5.  A DTT reduction protocol was established to unmask N-protein bound by antibody in serum by 
doing a control experiment with recombinant antigen and capture antibody spiked into sample matrix.  
N-protein concentration measured in serum was reduced after co-spiking with antibody, indicative of 
epitope masking. Adding DTT to the sample rescued 63% of the signal loss, indicating that this treatment 
could unmask antigen in seroconverted samples.   
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Table S2. Serum from COVID-19-negative donors serologically confirmed to have been infected with 
common respiratory viruses, demonstrating no cross-reactivity. 
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Table S3. Serum from COVID-19-negative donors serologically confirmed to have been infected with 
common coronaviruses, demonstrating no cross-reactivity. 
Sample ID 
SARS-
CoV-2 
N 
Protei
n 
Conc 
(pg/m
L) 
VAXARR
AY 
CORONA
VIRUS 
HKU + 
VAXARRAY 
CORONAVI
RUS HKU 
S/B RATIO 
(>=3.0 
positive) 
VAXARRAY 
CORONAVI
RUS OC43 + 
VAXARRAY 
CORONAVI
RUS OC43 
S/B RATIO 
(>=3.0 
positive) 
VAXARRAY 
CORONAVI
RUS 229E + 
VAXARRAY 
CORONAVI
RUS 229E 
S/B RATIO 
(>=3.0 
positive) 
VAXARRAY 
CORONAVI
RUS NL63 + 
VAXARRAY 
CORONAVI
RUS NL63 
S/B RATIO 
(>=3.0 
positive) 
Donor 1 <LoD NO 2.5 NO 1.9 YES 5.3 NO 2.7 
Donor 2 <LoD NO 2.7 YES 7 YES 13.3 NO 1.4 
Donor 3 <LoD NO 1.7 YES 4.2 YES 3.5 NO 2.5 
Donor 4 <LoD NO 2.5 NO 2.9 YES 5.8 NO 2.1 
Donor 5 <LoD NO 2.7 YES 9.8 YES 12.8 NO 2.8 
Donor 6 0.446 YES 4.2 YES 4.5 YES 4.5 YES 3 
Donor 7 <LoD YES 4.6 YES 4.7 YES 4.7 YES 3.7 
Donor 8 0.272 YES 6.4 YES 5.8 YES 6.5 YES 6.5 
Donor 9 <LoD YES 9.4 YES 9.5 YES 9.5 YES 9.5 
Donor 10 <LoD YES 3.7 YES 3.8 YES 3.8 NO 2.1 
Donor 11 <LoD YES 3.2 YES 8.8 YES 8.8 YES 3.7 
Donor 12 <LoD YES 7.5 YES 10.1 YES 10.1 YES 3.1 
Donor 13 <LoD YES 10.8 YES 10.9 YES 10.9 YES 10.9 
Donor 14 <LoD YES 4.4 YES 4.6 YES 4.6 YES 4.6 
Donor 15 <LoD YES 5.4 YES 3.3 YES 5.5 NO 2.8 
Donor 16 <LoD YES 8.6 YES 11.5 YES 11.5 YES 8.4 
Donor 17 0.481 YES 3.1 YES 4.5 YES 5.1 YES 3.5 
Donor 18 <LoD YES 6.2 YES 10.9 YES 10.9 YES 4.2 
Donor 19 <LoD YES 7.9 YES 8 YES 8 YES 8 
Donor 20 <LoD YES 9.3 YES 9.4 YES 9.4 YES 3.1 
Donor 21 0.062 YES 3.8 YES 5.1 YES 6.2 YES 6.2 
Donor 22 <LoD YES 3.7 YES 5.1 YES 5.1 YES 4.8 
Donor 23 <LoD YES 10.7 YES 10.8 YES 9.7 YES 4 
Donor 24 <LoD YES 5.2 YES 6.5 YES 6.5 YES 5.9 
Donor 25 <LoD YES 8.3 YES 8.4 YES 8.4 YES 5 
Donor 26 <LoD YES 12.1 YES 15.3 YES 15.3 YES 7.5 
Donor 27 <LoD YES 5.4 YES 7.8 YES 7.8 YES 5.2 
Donor 28 <LoD YES 4.7 YES 4.8 YES 4.9 YES 4 
Donor 29 <LoD YES 4.1 YES 4.2 YES 4.2 YES 4.2 
Donor 30 <LoD YES 4.5 YES 5.4 YES 5.4 YES 5.4 
Donor 31 <LoD YES 8.1 YES 12.7 YES 12.8 YES 8.4 
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Table S4.  Inactivated, cultured virus was purchased from Zeptometrix, and tested for cross-reactivity at 
the TCID50 levels listed.  No cross-reactivity was observed.  
  
Virus Description Vendor Cat# Titer Tested 
TCID50/mL 
Conc Measured by N 
antigen Assay 
Serum Plasma 
Adenovirus Type 07 
(Species B) Culture Fluid 
Zeptometrix 0810021CF
HI 
3.52E+04 <LoD <LoD 
Enterovirus Type 68 (2007 
Isolate) Culture Fluid 
Zeptometrix 0810237CF
HI 
3.78E+05 <LoD <LoD 
Influenza A H1N1 (New 
Cal/20/99) Culture Fluid 
Zeptometrix 0810036CF
HI 
2.88E+05 <LoD <LoD 
Influenza B (Florida/02/06) 
Culture Fluid 
Zeptometrix 0810037CF
HI 
3.52E+04 <LoD <LoD 
Parainfluenza Virus Type 1 
Culture Fluid 
Zeptometrix 0810014CF
HI 
2.28E+06 <LoD <LoD 
Parainfluenza Virus Type 2 
Culture Fluid 
Zeptometrix 0810015CF
HI 
2.88E+05 <LoD <LoD 
Parainfluenza Virus Type 3 
Culture Fluid 
Zeptometrix 0810016CF
HI 
1.65E+06 <LoD <LoD 
Parainfluenza Virus Type 
4A Culture Fluid 
Zeptometrix 0810060CF
HI 
7.05E+05 <LoD <LoD 
Respiratory Syncytial Virus 
Type A (Isolate: 2006 
Isolate) Culture Fluid 
Zeptometrix 0810040AC
FHI 
9.50E+05 <LoD <LoD 
Rhinovirus Type 1A Culture 
Fluid 
Zeptometrix 0810012CF
NHI 
8.88E+04 <LoD <LoD 
Coronavirus (Strain: 229E) 
Culture Fluid 
Zeptometrix 0810229CF
HI 
1.04E+05 <LoD <LoD 
Coronavirus (Strain: OC43) 
Culture Fluid 
Zeptometrix 0810024CF
HI 
2.63E+05 <LoD <LoD 
Coronavirus (Strain: NL63) 
Culture Fluid  
Zeptometrix 0810228CF
HI 
4.25E+04 <LoD <LoD 
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Table S5.  N-protein and SARS-CoV-2 specific IgG concentrations measured in the CTCH cohort for all 
donors and both collections. 
 
Donor ID 
Collection One Collection Two 
days 
from 
symptom 
days 
from PCR 
NP pg/ml Spk IgG 
days 
from 
symptom 
days 
from last 
PCR 
NP pg/ml Spk IgG 
1 7 7 4226.08 0.06 14 14 4.62 13.41 
2 8 7 2811.23 0.00 intubated 
3 6 6 186.14 0.03 13 13 7.41 0.14 
4 9 6 3933.59 0.01 died 
5   6 677.47 0.03   13 925 0.11 
6   5 11235.56 0.01 died 
7   5 154.47 0.03   12 72.2 0.06 
8 4 5 3349.23 0.01 Opted out of study --> died 
9   5 3896.05 0.03   12 1051 0.14 
11   5 6658.056 0.208 died 
12 -3 5 6.260 0.037 4 4 308 0.002 
13   5 0.010 0.001   12 0.01 0.005 
14   5 0.010 0.014   4 0.01 0.002 
15   5 0.040 0.024   4 0.01 0.021 
16   5 0.010 0.011   4 0.260 0.015 
17   5 0.040 0.005   4 0.01 0.013 
18   5 0.010 0.000   4 0.074 0.000 
19   5 0.010 0.019   4 0.01 0.012 
20   5 0.010 0.024   4 0.01 0.009 
21   5 0.010 0.012   4 0.074 0.011 
22           4 0.01 0.005 
23           17 0.993 0.702 
24           4 44.4 0.002 
25           4 0.01 0.031 
26         0 0 167 0.003 
27           11 0.01 0.054 
28           4 0.01 0.144 
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